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Lupus nephritisAbstract Aim of the work: To analyze the level of interleukin 22 (IL-22) in sera of systemic lupus
erythematosus (SLE) patients and to associate its level to disease activity, skin involvement and
lupus nephritis.
Patients and methods: The study included 70 SLE patients under treatment with disease-
modifying antirheumatic drugs and in 50 age and sex matched healthy controls. Patients were
assessed for clinical and laboratory variables including the erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), Antinuclear Antibodies (ANA), and anti-double stranded deoxyribonu-
cleic acid (ds-DNA). The SLE disease activity index (SLEDAI) was evaluated. Level of IL22 in
patients and controls sera was investigated by ELISA.
Results: The 70 patients were 64 women and 6 men with a mean age of 27.2 ± 8.2 years. Levels
of IL-22 were significantly increased in sera of SLE patients compared to controls (median 162 pg/
mL and 58 pg/mL, respectively; p< 0.001). IL-22 significantly correlated with the SLEDAI as well
as with ESR and CRP (r= 0.41 and p= 0.016; r= 0.42 and p= 0.01; r= 0.996 and p< 0.001,
respectively). IL-22 level revealed a significant association with skin involvement (p< 0.001) and
with the absence of lupus nephritis (p= 0.007).
Conclusion: Our data suggest that increased serum IL-22 may contribute to the pathogenesis of
SLE. Its elevated serum level allows discrimination between patients with different clinical and lab-
oratory measures and indicates the potential of IL-22 as an additional tool for assessment of activ-
ity in SLE. IL22 in serum seems to be a significant index reflecting skin and renal involvement in
SLE.
 2016 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).xpensive
2 I.I. El-Gazzar et al.1. Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune
disease, characterized by a multitude of autoantibody produc-
tion, complement activation and immune-complex deposition,
which causes tissue and organ damage. The etiology and
pathogenic mechanisms of SLE have not yet been clearly elu-
cidated. Cytokines produced by abnormal T-helper (Th) cells
have been shown to be involved in the pathogenesis of SLE [1].
Unregulated T-cell responses or overwhelming cytokines
secreted by T cells and other cell sources are associated with
many autoimmune collagen diseases. Among the 2 groups of
CD4+ T cells, T helper 1 (Th1) cells were believed to a main
drive of autoimmune diseases [2–4]. Consequently, the identifi-
cation of newer effector T-cell subsets such as Th17 and Th22
cells brings new insights into these diseases [5]. Th22 cells, a
new subset of CD4+ T-helper cells, are differentiated from
naı¨ve T cells in response to tumor necrosis factor-a (TNF-a)
and interleukin-6 (IL-6), and are characterized by secretion of
IL-22 but not IL-17 or interferon-c (IFN-c) [6–8]. Th22 cells
also produce cytokines IL-26 and IL-13 in addition to IL-22 [8].
IL-22, being the most important functional cytokine of
Th22 cells [9], acts synergistically with IL-17, TNF-a, and
IFN-c in a proinflammatory context [10] and plays an
important role in autoimmune diseases. These play a
pro-inflammatory role in autoimmune diseases via the
up-regulation of additional proinflammatory and neutrophil-
recruiting cytokines and chemokines [11]. IL-22 is an IL-10
family cytokine member, being initially recognized as IL-10
related T-cell-derived inducible factor (IL-TIF) [12,13].
The IL-22 signaling pathways affect multiple molecular
processes in autoimmune diseases [14–18], therefore, manipu-
lation of IL-22 and its signaling pathways may have the
potential to provide treatments for autoimmune diseases.
Recent studies reported that IL-22 showed to be implicated
in and differentially expressed in many autoimmune diseases
[19–21]. IL-22 gene knockout or inhibition of IL-22 proteins
could considerably ameliorate autoimmune diseases in many
murine models [22,23]. However, most of these data do not
determine whether IL-22 is mediating the inflammation itself,
or is a by-product of the inflammation [24]. Abnormal
expression of Th22 cells was seen in peripheral blood of some
autoimmune diseases including psoriasis [25], systemic
sclerosis (SSc) [26] and rheumatoid arthritis (RA) [27,28]. At
the same time Th22 together with its abnormal production
of IL22 seem to be a more significant index to predict the tissue
involvement in SLE [11].
2. Patients and methods
A total of 70 SLE patients were recruited from the inpatient
Rheumatology Department and Outpatient Clinic of Rheuma-
tology, Kasr Al Aini Teaching Hospital, Medical School Cairo
University. An additional 50 healthy volunteers, comparable
to SLE patients with age and sex were involved in our study.
Patients meeting the 1997 American College of Rheumatology
(ACR) classification criteria for SLE [29] were recruited and
their demographic features, clinical data and current medica-
tions reported. Systemic lupus erythematosus disease activity
index 2000 (SLEDAI 2K) was used to determine the global
disease activity [30]. Active SLE was defined by SLEDAI P5Please cite this article in press as: El-Gazzar II et al. IL22 in Egyptian SLE patients, c
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very high P20. Complicated lupus nephritis was defined
according to the ACR criteria i.e., any one of the following:
(1) persistent proteinuriaP0.5 g/day; (2) the presence of active
cellular casts; (3) biopsy evidence of lupus nephritis [31]. Com-
plicated lupus skin disease was defined according to rash shape
and/or skin histopathology. All SLE patients were under
immunomodulatory drugs. All subjects were excluded if she/
he had a history of myositis, systemic sclerosis or other
autoimmune diseases or a recent infection. Volunteers who
denied any autoimmune disease and active infection and are
not undergoing treatment with immunomodulatory drugs for
any known condition were recruited as controls. Written
informed consent was obtained from individual participants.
The study was approved by the local ethics committee and
conforms to the 1995 Helsinki declaration.
Blood samples were obtained from patients and controls
for routine laboratory tests of full blood cell counts, erythro-
cyte sedimentation rate (ESR) and the quantitation of serum
C-reactive protein (CRP), presence of Antinuclear Antibodies
(ANA), anti-Smith (anti-Sm) and anti-double stranded
deoxyribonucleic acid (anti-ds DNA) antibodies. The normal
range of CRP and ESR was 0–15 mg/L and 0–10 mm/h,
respectively. The presence of serum ANA and anti-dsDNA
was determined by indirect immunofluorescence using special
kits and the presence of anti-Sm antibodies by enzyme linked
immunosorbent assay (ELISA) kit according to the manufac-
turer’s instructions. The concentrations of serum CRP were
determined by scatter turbidimetry (Siemens Healthcare Diag-
nostics Products, GmbH, Germany).
The concentrations of serum IL-22 in individual partici-
pants were determined by ELISA using specific cytokine kits,
according to the manufacturer’s instructions [Human IL22
ELISA CUSABIO, USA, Catalog number (CSB-E 13418h)].
The detection range of this kit was 15.6–1000 pg/mL.
2.1. Statistical analysis
Datamanagement and analysis were performed using Statistical
Package for Social Sciences (SPSS) vs. 21. Comparisons
between 2 groups were done by the Mann–Whitney test. Chi-
square or Fisher’s exact test was used to compare between the
groups with respect to categorical data. Tomeasure the strength
of the association of IL22 and the other numerical variables,
Spearman’s correlation coefficient was computed. All p-values
are two-sided. P-values <0.05 will be considered significant.
3. Results
A total of 70 patients with SLE (64 women, 6 men; mean age
27.2 and standard deviation 8.2 years) and 50 comparable in
gender- and age healthy subjects (44 women and 6 men; mean
age 32.7 and standard deviation 7.4 years) were recruited and
their demographic features, clinical characteristics, disease
activity and serum IL-22 level are shown in Table 1. The white
blood cell (WBC) count was comparable between patients and
controls while the CRP was significantly higher in the patients.
The concentrations of IL-22 in sera of the patients with
SLE were significantly higher than that in the controls, median
162 pg/mL (range: 50–960 pg/mL) and 58 pg/mL (range:
15–123 pg/mL), respectively; p< 0.001 (Fig. 1).ould it reflect disease activity, skin or renal involvement or is it only an expensive
001
Table 1 Demographic features, clinical characteristics, disease activity and serum IL-22 level of the SLE patients and control.
Median (range) or n (%) SLE patients (n= 70) Controls (n= 50)
Male/female 6/64 6/44
Age (year) 26 (12–46) 32 (21–48)
Disease duration (years) 5 (1–20) –
CRP (mg/L) 94 (30–385)* 31 (6–73)
ESR (mm/h) 45 (15–125) 25 (2–40)
Positive anti-dsDNA 25 (71.4) –
Positive anti-Sm 9 (25.7) –
Positive ANA 35 (100) 0 (0)
WBC (x109/L) 6.4 (2.3–15) 6.3 (4.1–10.8)
SLEDAI 2 K 20 (2–38) –
IL-22 conc (pg/mL) 162 (50–960)* 58 (15.6–123)
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SLEDAI 2K: SLE disease activity index 2000, ND, not determined.
* Significantly different from the control at p< 0.001. All of the patients had clinical symptoms for more than one year
Figure 1 Serum IL-22 levels in SLE patients and controls.
IL22 in SLE patients 3The results revealed that the serum level of IL-22 was signif-
icantly increased in patients with lupus skin disease (n= 44)
[median, 273 pg/mL (range 65–960); p< 0.001] in comparison
to patients without skin involvement, while its level is
significantly lower in patients showing lupus nephritis
(n= 30) [median,115 pg/mL (range, 50–725); p= 0.007] than
in those who didn’t have kidney affection (Table 2).
Our study revealed a significant correlation of the serum
IL-22 levels with the SLEDAI 2K score (r= 0.41,
p= 0.016) (Fig. 2), with the ESR levels (r= 0.42,
p= 0.012) (Fig. 3) and with the CRP level (r= 0.996,
p< 0.001) (Fig. 4).Table 2 Serum IL22 level in association with skin involvement and
SLE patients (n= 70)
Present
N Median Range
Skin involvement 44 273 (65–960)
Lupus nephritis 30 115 (50–725)
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The spectrum of autoimmune diseases includes a large variety
of diseases such as SLE, RA, multiple sclerosis (MS), Sjo¨gren’s
syndrome (SS) and psoriasis displaying different clinical fea-
tures. Besides the significant clinical differences, there are also
many clinical features and pathogenic mechanisms that over-
lap among these autoimmune diseases and many inflammatory
cytokines and chemokines are involved in their pathogenesis.
A better understanding of the pathogenesis of autoimmune
diseases is needed for the development of new treatment
modalities and a better outcome [32,33]. A recent unique cyto-
kine, IL-22, has been implicated in the pathogenesis of autoim-
mune inflammatory diseases. New research has suggested that
different types of IL22+ CD4+ T-cells may collaborate and
contribute to the pathogenesis of SLE in humans [11,34].
In our study, we measured the concentrations of serum IL-
22 in SLE patients and compared them to those of healthy
controls. The levels were significantly higher in the patients.
Our findings are in agreement with a recent study that reported
increased plasma levels of IL-22 in 22 SLE patients [34]. In
contrast, other studies reported unchanged serum IL-22 in
SLE compared with controls, and no significant difference
between active and inactive patients [11,35–37]. The difference
in the levels of plasma IL-22 between our study and that of
others may stem from the different populations of patients
studied, varying disease severities, and durations as well as
therapeutic status. We are interested in further investigating
the dynamic changes in the levels of serum IL-22 in SLE
patients with different stages and activities. All the current
patients were recruited from the inpatient service with more
severe clinical symptoms.
Our novel data suggest that serum IL-22 levels may be used
as a good biomarker for the evaluation of SLE disease activity.lupus nephritis.
Absent p
N Median Range
26 115 (50–265) <0.001
40 250 (100–960) 0.007
uld it reflect disease activity, skin or renal involvement or is it only an expensive
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Figure 2 Correlation between serum IL-22 levels and the
SLEDAI score in SLE patients.
Figure 3 Correlation between serum IL22 levels and ESR levels
among SLE patients.
Figure 4 Correlation of serum IL-22 levels with the CRP level.
4 I.I. El-Gazzar et al.A significant correlation was found between serum IL-22 level
and the SLEDAI 2K. This agrees with the work of Zhao et al.
who found a higher IL22 levels in sera of SLE patients than
controls and reported that the percentages of IL-22+ CD4+
T-cells and Th17 cells significantly correlated with the SLE-
DAI [34]. However, this is not in agreement with the data
reported by Yang et al., who couldn’t discover any significant
difference in serum IL-22 between active and inactive SLE
patients [11]. The difference may stem from the different dis-
ease duration as in the study of Yang and coworkers most
of their patients were of new-onset and not receiving immuno-
suppressive or immunomodulatory drugs for 6 months. The
difference of populations of patients with various genetic back-
grounds may also play a role.Please cite this article in press as: El-Gazzar II et al. IL22 in Egyptian SLE patients, c
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significantly correlated with the CRP and ESR values in SLE
patients. Given that CRP and ESR are valuable biomarkers
of inflammation and an ongoing inflammatory process, this
correlation possibly indicates the important role of IL-22 in
the inflammatory process responsible for the clinical picture
of SLE. These findings were consistent with the study reported
by Zhao et al. [34] but in disagreement with previous studies
that have shown significantly lower concentrations of CRP
in SLE patients than in controls [35–37].
Regarding tissue involvement, our study revealed elevated
serum IL-22 in patients with lupus skin rash. Th22 cells express
the chemokine receptors CCR6, CCR4 and CCR10 [6,8]. The
expression of two skin-homing receptors CCR4 and CCR10
on the surface of Th22 cells implies that Th22 cells will inevitably
migrate to the skin. Therefore, we speculate that increased Th22
cells of peripheral blood in SLE patients with lupus skin disease
may indeed reach the skin and could be a significant factor in the
development of lupus skin diseases. This was consistent with the
study of Yang et al. who speculated that increased Th22 cells of
peripheral blood in SLE patients with lupus skin disease could
be a significant factor in its development [11]. In his study
increasing number of Th22 cells was in accordance to the ele-
vated serum IL-22 concentration observed in patients with sole
lupus skin diseases. In addition, IL-22R1 is only expressed on
stromal cells, which include keratinocytes, myofibroblasts and
epithelial cells, but not on hematological cells [38]. IL-22 also
provides unidirectional signaling from the immune system to
the stroma by downstream signal transducer and activator of
transcription (STAT3) activation in stromal cells resulting in
the secretion of a variety of factors that include antimicrobial
peptides and chemokines [39,40]. Consequently, this stromal
IL-22/STAT3 pathway can be exemplified by induction of a
psoriasis-like autoimmune disease [41,42]. A further implication
of our study shows that Th22 cells mightmediate dermal inflam-
mation through the activation of IL-22/STAT3 pathway in
lupus skin disease. Furthermore, another main cytokine,
TNF-a, secreted by Th22 cells, is also an important pathogenic
cytokine in lupus skin disease. It could enhance the responsive-
ness of the keratinocytes to IL-22 via up-regulation of IL-22
receptor and signal transduction element expression [43], as well
as continuing to amplify and/or prolong these IL-22 effects. In
addition, TNF-a also induces Intercellular Adhesion Molecule
1 (ICAM-1) expression, dendritic cells (DCs) migration and
lymphocyte infiltration [44,45], any of which can contribute to
skin lesion. Th22 cells, therefore, may be involved in the patho-
genesis of lupus skin disease by secretion of proinflammatory
cytokines such as IL-22 and TNF-a.
On the other hand, the level of serum IL-22 in patients of
lupus nephritis showed a significant reduction in comparison
to patients who didn’t show kidney affection. In humans, the
kidney expresses high levels of IL-22R1 [38]. The decreased
serum IL-22 level in lupus nephritis patients indicated that
IL-22 might be a protection against lupus nephritis. Our
results are in agreement with Yang et al. who reported a
decreased number of Th22 cells in peripheral blood of patients
with lupus nephritis [11]. Researchers report that the differen-
tiation of Th22 cells was induced by DCs in a dependent IL-6
and TNF-a way, and the subsequent removal of TNF-a min-
imized the development of Th22 cells [hh3 14]. Decreased
levels of TNF-a in the peripheral blood were already found
in lupus nephritis [46,47], which explains the presence of lowould it reflect disease activity, skin or renal involvement or is it only an expensive
001
IL22 in SLE patients 5number of Th22 cells in peripheral blood of lupus nephritis
patients and hence low serum level of IL-22 [11].
In conclusion, our results validate the reliability of previous
scientific findings [48,49]. What caught our attention was the
significant correlation between the elevation of IL22 and C-
reactive protein, and since CRP is not usually elevated in
SLE, the correlation with IL-22 is strange. Is IL-22 just a result
of inflammation and not the cause? On the other hand, we
shall not ignore that our study profoundly supports the view
that IL-22 might be a good index to reflect skin and renal
involvement in SLE patients.
The limitation of this investigation is its small sample size.
We are interested in further investigating the dynamic changes
in the levels of plasma IL-22 in patients with different stages
and activities of SLE. Therefore, future prospective cohort
studies with large sample sizes are necessary.
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